



Corporate Satellite Symposium

New Frontiers for AmplideX® Technology: Portfolio Expansion to New High Complexity Targets

Saturday, June 16 | 10.00 - 11.30 | Brown Room 1



Evaluation of High Performing PCR-only AmplideX Workflow for Myotonic Dystrophy as a Replacement for Southern Blot

*Isabel Marques, ErCLG, PhD
Clinical Laboratory Geneticist in Medical Genetics Center,
Centro Hospitalar do Porto E.P.E., Porto, Portugal*



Simple, Rapid, and Scalable SMN1/SMN2 Copy Number Assays: Quantitative PCR/CE Workflows Compatible with AmplideX FMR1 Repeat Genotyping

*Gary J. Latham, PhD
Senior Vice President, Research and Development, Asuragen*

For more information about Asuragen's growing AmplideX portfolio and our presence
at the ESHG annual meeting visit www.asuragen.com/eshg18

*Products are currently under development. Future
availability and performance cannot be ensured.

AmplideX®
Sensitive | Accurate | Complete